FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377018076> ?p ?o ?g. }

• W4377018076 endingPage "110266" @default.
• W4377018076 startingPage "110266" @default.
• W4377018076 abstract "Progressive multiple sclerosis (PMS) is a debilitating condition characterized by progressively worsening symptoms. Monoclonal antibodies are novel therapies for MS, but their safety and efficacy in the progressive form have not been comprehensively studied. In this systematic review, we aimed to evaluate the available evidence regarding monoclonal antibody treatment for PMS. After registration of the study protocol in PROSPERO, we systematically searched three major databases for clinical trials involving monoclonal antibodies administration for PMS treatment. All the retrieved results were imported into the EndNote reference manager. After removing the duplicates, two independent researchers did the study selection and data extraction. The risk of bias was assessed using the Joanna Briggs Institute (JBI) checklist. Of the 1846 studies in the preliminary search, 13 clinical trials investigating monoclonal antibodies (Ocrelizumab, Natalizumab, Rituximab, and Alemtuzumab) in PMS patients were included. Ocrelizumab was significantly effective in reducing clinical disease progression measures in primary PMS patients. The results for Rituximab were not completely reassuring and only showed significant changes for some endpoints on MRI and clinical measures. Natalizumab decreased the relapse rate and improved MRI features for secondary PMS patients, but not clinical endpoints. The studies on Alemtuzumab treatment revealed conflicting outcomes, with improvements observed in MRI endpoints but clinical worsening in patients. Additionally, among the studied adverse events, upper respiratory infections, urinary tract infections, and nasopharyngitis were frequently reported. Based on our findings, Ocrelizumab is the most efficient monoclonal antibody for primary PMS, although it is associated with a higher risk of infection. While other monoclonal antibodies did not show significant promise in treating PMS, more research is necessary." @default.
• W4377018076 created "2023-05-19" @default.
• W4377018076 creator A5003822995 @default.
• W4377018076 creator A5052882937 @default.
• W4377018076 creator A5080330903 @default.
• W4377018076 creator A5082925425 @default.
• W4377018076 creator A5091971985 @default.
• W4377018076 date "2023-07-01" @default.
• W4377018076 modified "2023-09-30" @default.
• W4377018076 title "A systematic review of the safety and efficacy of monoclonal antibodies for progressive multiple sclerosis" @default.
• W4377018076 cites W1554919938 @default.
• W4377018076 cites W1968571773 @default.
• W4377018076 cites W2006173610 @default.
• W4377018076 cites W2006843288 @default.
• W4377018076 cites W2010943878 @default.
• W4377018076 cites W2038935322 @default.
• W4377018076 cites W2042725832 @default.
• W4377018076 cites W2067673653 @default.
• W4377018076 cites W2069839237 @default.
• W4377018076 cites W2080337955 @default.
• W4377018076 cites W2102697241 @default.
• W4377018076 cites W2103758700 @default.
• W4377018076 cites W2106467284 @default.
• W4377018076 cites W2107008240 @default.
• W4377018076 cites W2128402413 @default.
• W4377018076 cites W2140051179 @default.
• W4377018076 cites W2143953700 @default.
• W4377018076 cites W2148563799 @default.
• W4377018076 cites W2149942972 @default.
• W4377018076 cites W2278613505 @default.
• W4377018076 cites W2313484897 @default.
• W4377018076 cites W2345282462 @default.
• W4377018076 cites W2553410079 @default.
• W4377018076 cites W2565433170 @default.
• W4377018076 cites W2783472197 @default.
• W4377018076 cites W27919971 @default.
• W4377018076 cites W2792424729 @default.
• W4377018076 cites W2793526309 @default.
• W4377018076 cites W2804050703 @default.
• W4377018076 cites W2804387447 @default.
• W4377018076 cites W2807882529 @default.
• W4377018076 cites W2889190248 @default.
• W4377018076 cites W2889214655 @default.
• W4377018076 cites W2896455370 @default.
• W4377018076 cites W2901155618 @default.
• W4377018076 cites W2907044047 @default.
• W4377018076 cites W2909270098 @default.
• W4377018076 cites W2912026765 @default.
• W4377018076 cites W2913489076 @default.
• W4377018076 cites W2955874948 @default.
• W4377018076 cites W2978140831 @default.
• W4377018076 cites W3011073921 @default.
• W4377018076 cites W3012254007 @default.
• W4377018076 cites W3016526220 @default.
• W4377018076 cites W3048887029 @default.
• W4377018076 cites W3084143806 @default.
• W4377018076 cites W3092316673 @default.
• W4377018076 cites W3096310943 @default.
• W4377018076 cites W3113553077 @default.
• W4377018076 cites W3116218681 @default.
• W4377018076 cites W3163234560 @default.
• W4377018076 cites W3165109500 @default.
• W4377018076 cites W3191878299 @default.
• W4377018076 cites W3198774415 @default.
• W4377018076 cites W4214834623 @default.
• W4377018076 cites W4253381763 @default.
• W4377018076 cites W4255801462 @default.
• W4377018076 cites W4281814171 @default.
• W4377018076 cites W60759546 @default.
• W4377018076 doi "https://doi.org/10.1016/j.intimp.2023.110266" @default.
• W4377018076 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37209514" @default.
• W4377018076 hasPublicationYear "2023" @default.
• W4377018076 type Work @default.
• W4377018076 citedByCount "0" @default.
• W4377018076 crossrefType "journal-article" @default.
• W4377018076 hasAuthorship W4377018076A5003822995 @default.
• W4377018076 hasAuthorship W4377018076A5052882937 @default.
• W4377018076 hasAuthorship W4377018076A5080330903 @default.
• W4377018076 hasAuthorship W4377018076A5082925425 @default.
• W4377018076 hasAuthorship W4377018076A5091971985 @default.
• W4377018076 hasConcept C126322002 @default.
• W4377018076 hasConcept C143998085 @default.
• W4377018076 hasConcept C159654299 @default.
• W4377018076 hasConcept C197934379 @default.
• W4377018076 hasConcept C203014093 @default.
• W4377018076 hasConcept C203092338 @default.
• W4377018076 hasConcept C2778843634 @default.
• W4377018076 hasConcept C2779015954 @default.
• W4377018076 hasConcept C2779338263 @default.
• W4377018076 hasConcept C2780640218 @default.
• W4377018076 hasConcept C2780653079 @default.
• W4377018076 hasConcept C2781004633 @default.
• W4377018076 hasConcept C2911091166 @default.
• W4377018076 hasConcept C535046627 @default.
• W4377018076 hasConcept C542903549 @default.
• W4377018076 hasConcept C71924100 @default.
• W4377018076 hasConceptScore W4377018076C126322002 @default.
• W4377018076 hasConceptScore W4377018076C143998085 @default.

• next